Menu
Search
|

Menu

Close
X

Cleveland Biolabs Inc CBLI.OQ (NASDAQ Stock Exchange Capital Market)

1.03 USD
-- (--)
As of Sep 18
Previous Close 1.03
Open --
Volume --
3m Avg Volume 1,799
Today’s High --
Today’s Low --
52 Week High 2.12
52 Week Low 1.00
Shares Outstanding (mil) 11.30
Market Capitalization (mil) 15.93
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
1
FY17
2
FY16
4
EPS (USD)
FY19
-0.077
FY18
-0.320
FY17
-0.867
FY16
-0.242
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
14.37
7.90
Price to Book (MRQ)
vs sector
--
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
--
17.64
LT Debt to Equity (MRQ)
vs sector
--
12.61
Return on Investment (TTM)
vs sector
--
12.69
Return on Equity (TTM)
vs sector
--
17.13

EXECUTIVE LEADERSHIP

Langdon Miller
President, Since 2015
Salary: $119,550.00
Bonus: --
Yakov Kogan
Chief Executive Officer, Chief Financial Officer, Secretary, Since 2017
Salary: $276,000.00
Bonus: --
Andrei Gudkov
Chief Scientific Officer, Since 2003
Salary: $110,941.00
Bonus: --
Ivan Fedyunin
Director, Since 2018
Salary: --
Bonus: --
Alexander Andryushechkin
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

73 High St
BUFFALO   NY   14203-1149

Phone: +1716.8496810

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

SPONSORED STORIES